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Hematopoiesis & Hematopoietic Stem Cells
Introduction
Hematopoietic stem cells (HSCs) and their down-stream
progenitors (HSPCs) are dependent on their specific micro-
environment, the niche, to balance self-renewal and differen-
tiation.1 HSCs reside in the bone marrow (BM) either in the
BM cavity in contact with endothelial, perivascular, sinu-
soidal, reticular and CAR cells (CXCL12-abundant reticular
cells),2 i.e. the vascular niche, or close to the endosteal surface
in direct contact with osteoblasts (SNOs)3,4 and osteoclasts,
i.e. the endosteal niche. 
Alterations in osteoblast numbers and bone mass correlate
with HSC numbers.3,4 Therefore, the number of HSCs could
be centrally controlled by hormones affecting bone mass.
Estrogens are well known modulators of bone mass5 and
long-term treatment leads to an increase in endosteal bone
mass.5,6 To investigate whether estradiol also influences
HSCs, we analyzed estradiol treated mice. Although bone
mass was strongly increased, there was no alteration in the
numbers of HSPCs located in the endosteal niche. In contrast,
the numbers of HSPCs in the vascular niche were significant-
ly increased due to enhanced cycling of HSPCs and an upreg-
ulation of adhesion molecules in the stromal cell compart-
ment, indicating that estradiol acts on HSPCs independent of
its effects on bone. 
Design and Methods
Animal treatments
Animal experiments were performed according to accepted standards
of animal welfare and with the permission of the authorities of
Thüringen. Estrogen treatment was given for four weeks by subcuta-
neous implantation of slow-release pellets resulting in a calculated dose
of 0.24 mg/kg/d (0.36 mg; 60-day release; Innovative Research of
America, Inc.) in 10-12 week old female C57BL/6 or CD45.1 (wild-type)
mice and in ERα- and ERβ-knockout, ERα−loxPRunx2Cre mice.7-10 Mice
received short-term treatment with estradiol 5 mg/kg (Sigma) i.p. daily.
Bone sections and von Kossa staining
Lumbar vertebral bodies (L3-L5) and one tibia of each mouse were
processed and stained, and bone histomorphometry was performed,
all as previously described.9
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Hematopoietic stem and progenitor cells reside in vascular and
endosteal niches in the bone marrow. Factors affecting bone
remodeling were reported to influence numbers and mobiliza-
tion of hematopoietic stem cells. We therefore analyzed the
effects of estradiol acting anabolic on bone integrity. Here we
observe that estradiol increases progenitor cell numbers in the
vascular but not in the endosteal compartment independent of
its estrogen receptor α-dependent anabolic bone effects.
Hematopoietic progenitors capable of reconstituting lethally
irradiated mice are increased by enhanced cell cycle entry, lead-
ing to a diminished long-term reconstitution potential after
serial transplantation. We demonstrate that estradiol action on
stromal cells potently favors hematopoietic progenitor/stem
cell frequency accompanied by enhanced expression of cell
adhesion molecules. Finally, estradiol treatment enhances
retention of hematopoietic stem cells in the vascular niche of
the bone marrow. We describe for the first time the mechanism
of estrogen action on hematopoietic stem and progenitor cells.
Key words: estradiol, bone mass, endosteal and vascular
niche, short-term, long-term, progenitors, CD34, adhesion
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Isolation of hematopoietic cells of the vascular
and endosteal niche
The flushed fraction of the BM from hindlimbs and humeri rep-
resents the cells from the vascular niche. Endosteal BM cells were
isolated as previously described.11 The digested fraction represents
the cells of the endosteal niche. 
Flow cytometry
Flow cytometry was performed as described.12 Monoclonal anti-
bodies from Natutec /eBioscience were: 
Gr1-FITC, B220-FITC, CD3-FITC, CD11b-FITC, Ter119-FITC,
Sca1-PE,CD117-APC, CD150-PE, CD150-APC, CD48-PE, CD48-
APC, CD45.1-FITC, B220-PE, Gr1-PE, CD11b-APC, CD4-PE,
CD8-APC.
Data were recorded with FACS-Canto II or FACS-Calibur (BD-
Biosciences) and analyzed by Flow Jo 8.0 flow cytometry software
(Tristar).
CAFC assay
Cobblestone area forming cell (CAFC) assay was performed as
described13 and frequency of HSC was calculated using Poisson
statistics.14
Homing-assay
BM cells were labeled with carboxyfluorescein succinimidyl
ester (CFSE) as previously described15,16 and injected (i.v.) into irra-
diated (8 Gy) estradiol treated recipients. After 15 h, BM was ana-
lyzed for CFSE-positive cells by flow cytometry.
Cell-cycle analysis
After LSK staining, BM cells were fixed, permeabilized, RNAse
A (Invitrogen) treated, and PI (probidium iodide, Invitrogen)
stained according to standard protocols and analyzed by flow
cytometry.  
Determination of competitive repopulation units
in limited dilution analysis 
Limited dilution analysis (LDA) was performed according to
standard protocols using four dilutions at 1:3, starting with 540,000
cells.14 For transplantation, lethally irradiated recipients were intra-
venously injected with BM cells from estradiol and control treated
mice.
Serial transplantation
Serial transplantation was performed as described17 using
CD45.1 recipients receiving 5¥106 BM cells from either control or
estradiol treated mice. Four months posttransplantation, recipients
were analyzed and 5¥106 BM cells were transplanted into second-
ary or third recipients. Reconstitution was analyzed in the blood
and BM for donor-derived B cells, T cells and granulocytes by flow
cytometry.
Results and Discussion
Estradiol increases bone mass in wild-type mice but 
does not affect bone adherent hematopoietic progenitor
(HSPCs) cells
To investigate the effects of a long-term treatment with
estradiol in C57BL/6-mice, animals were treated with 6 μg
estradiol per day for 30 days. This treatment leads to
strongly increased trabecular bone mass (Figure 1A, Online
Supplementary Table S1) which, given a similar number of
osteoblasts per bone surface, results in an increase in total
osteoblast numbers (Online Supplementary Table S1). This is
also shown by an increase in the bone formation rate,
demonstrating enhanced osteoblast activity (Online
Supplementary Table S1). Since intermittent parathyroid hor-
mone treatment indirectly influences HSPCs (LSK, lineage–/
Sca1+ / cKit+) by increasing trabecular bone,3,4 we expected a
profound effect of estradiol enhancing bone mass and con-
comitantly HSC numbers. Surprisingly, estradiol was not
seen to have any influence on the numbers of LSK-cells in
the endosteal stem cell niche (Figure 1B and C). This sug-
gests that the increased bone mass did not influence
endosteal HSC numbers. This was confirmed by unaltered
HSC frequency in CAFC (cobblestone area forming cell)
assay investigating endosteal bone marrow (BM) after estra-
diol treatment (data not shown).
Estradiol increases HSPCs with reconstitutive potential
in the vascular niche
In contrast, LSK cells of the vascular niche were increased
in percentages after estradiol exposure (Figure 1D and E)
and also increased in absolute numbers (Figure 1F). In par-
ticular, CD34–/lo LSK cells were increased in number (Figure
1G, Online Supplementary Figure S1A), whereas LT-HSCs
(CD48–CD150+CD34–/lo LSK) were not altered (Figure 1H,
Online Supplementary Figure S1B). Accordingly, the CAFC-
assay analyzed at Day 21 (Figure 1J) represents ST-HSCs
and confirmed the increase in HSPCs in the vascular BM of
estradiol treated mice. The CAFC assay analyzed at Day 35,
representing LT-HSCs (Figure 1I), showed no significant
changes from estradiol treatment. Thus, ST-HSCs rather
then LT-HSCs are increased in estradiol treated mice. 
Next, we tested whether estradiol increases HSPCs in vivo
by a limiting dilution analysis (LDA) determining the fre-
quency of competitive repopulating-units (CRUs). Mice
transplanted with different dilutions of BM cells from estra-
diol treated animals showed better reconstitution after four
months than mice receiving control treated BM (Figure 1K
and L). LDA showed a strong increase in CRU (as measure-
ment for HSCs, Figure 1L) in estradiol treated mice. Hence,
estradiol elevates numbers of functional HSCs in the vascu-
lar niche. 
Estradiol alters the cell cycle entry of LSK cells leading
to a decrease in long-term repopulating HSCs (LT-HSCs)
LSK cells of estradiol treated mice are significantly
stronger represented in S-phase compared to untreated
mice (Figure 1M). Additionally, more LSK-cells are present
in G2/M phase whereas there was a slight reduction in
G0/G1 cells. In conclusion, estradiol causes more HSPCs to
enter the S phase and, therefore, less progenitor and stem
cells are quiescent in the G0/G1-phase. 
We observed a significant decrease in donor-derived LSK
cells in the BM of the recipient mice after the third transplan-
tation with BM from estradiol treated mice (Figure 1N). Loss
of reconstitution potential mainly affected formation of
granulocytes but not the lymphoid lineage (Figure 1O). It has
been hypothesized that there are heterogeneous stem cell
populations consisting of myeloid biased LT-HSCs that are
forming cells of the myeloid lineage, and lymphoid-biased
LT-HSCs, preferentially forming cells of the lymphoid line-
age.18,19 This could indicate a selective suppressive effect of
estradiol on long-term repopulation of myeloid biased LT-
HSCs which is, however, not evident after measuring the
numbers of CD48–CD150+CD34–/lo LSK cells that remain
unchanged (Figure 1H, Online Supplementary Figure S1B). 
a. Illing et al.
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Figure 1. Estradiol increases the bone mass in wild-type mice and functional HSPCs in the vascular niche of the BM by an enhanced entry
into the cell cycle resulting in early exhaustion of LT-HSCs. (A) von Kossa staining for the calcium-content of the bones. Tibias of estradiol
treated mice show increased calcium-content due to increased bone mass. (B) Representative dot blots of the bone-adherent hematopoietic
cells stained for lineage-negative / Sca1-positive / cKit-positive cells (LSK-cells) isolated from estradiol and control treated mice. (C)
Summarized percentages of LSK-cells in the fraction of bone-adherent hematopoietic cells in control and estradiol treated mice (n=5). (D)
Representative dot blots of the cells of the vascular HSC-niche stained for lineage-negative / Sca1-positive / cKit-positive cells (LSK-cells)
isolated from estradiol and control treated mice. (E) Summarized percentages of LSK-cells in the vascular niche of control and estradiol
treated mice (n=5). (F) Absolute numbers of LSK-cells per hindlimb in the vascular niche from control and estradiol treated mice (n=5). (G,
H) Absolute numbers of CD34-/lo LSK cells (G) and CD48-CD150+CD34-/lo LSK cells (H) per hindlimb in the vascular niche from control and
estradiol treated mice (n=5). (I) Frequency of cobblestone area forming (CA-forming) colonies in the vascular niche of control and estradiol
treated mice after 35 days of coculture. (J) Frequency of cobblestone area forming (CA-forming) colonies in the vascular niche of control
and estradiol treated mice after 21 days of co-culture. (K) Percentages of donor-derived blood cells four months post transplantation with
BM from control and estradiol treated mice in decreasing dilutions (dilutions: 540000, 180000, 60000, 20000 cells per mouse; n per dilu-
tion=5). (L) Calculated frequency of colony repopulating units (CRU), according to Poisson Statistics,14 4 months post transplantation with
BM from control and estradiol treated mice. (M) Distribution of LSK-cells throughout G0/G1, G2/M and the S-phase of the cell cycle after
treatment of mice with estradiol (n=5). (N) Percentage of donor-derived (CD45.2-positive) LSK-cells after the third transplantation with BM
from control and estradiol treated mice (n=10). (O) Percentage of donor-derived (CD45.2-positive) granulocytes (Gr1/CD11b-pos. cells) and
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Estrogen receptors ERα and ERβ are redundant 
for the effects of estradiol on HSPC numbers 
in the vascular niche
Next, we tested the involvement of estrogen receptors
(ERα and ERβ)20-22 in estradiol effects on HPSCs. Despite
their well-established expression in bone, mRNA of both
receptors is expressed also in HPSCs at comparable levels to
that in ovaries, expressing high levels of ERα and ERβ
(Online Supplementary Figure S2A and B). ERβ deficient mice
displayed an increase in bone mass resulting in decreased
cellularity, as in wild-type mice (Figure 2A), there was no
alteration in endosteal HSPC numbers, and they showed
increased vascular HSC numbers upon estradiol treatment
(Figure 2B). In contrast, no increase in bone mass was
observed in ERα-knockout mice (Figure 2C) and neither
was any change seen in BM cellularity upon estradiol treat-
ment (Figure 2D). The frequency of endosteal HSCs was
also unaltered in ERα knockout mice (Figure 2E).
a. Illing et al.
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Figure 2. The ERα and the ERβ are redun-
dant for the increase of vascular HSPCs by
estradiol and estradiol increases the adhe-
sion of HSPCs in the vascular niche by upreg-
ulation of adhesion molecules. (A) Absolute
numbers of BM-cells per hindlimb in the vas-
cular niche from control and estradiol treat-
ed wild-type and ERβ-ko mice (n=5). (B)
Percentage of LSK-cells in the vascular niche
of control and estradiol treated wild-type and
ERβ-ko mice (n=5). (C) von Kossa staining
for the calcium content of the bone on the
tibia of control and estradiol treated wild-
type and ERα-Runx2cre-mice. (D) Absolute
numbers of BM-cells per hindlimb in the vas-
cular niche from control and estradiol treat-
ed wild-type and ERα-ko mice (n=5). (E)
Percentage of LSK-cells in the endosteal
niche of control and estradiol treated ERα-ko
mice (n=5). (F) Calculated frequency of
colony repopulating units (CRU), using
Poisson Statistics14 four months post trans-
plantation with BM from control and estradi-
ol treated wild-type and ERα-ko mice. CRU-
calculation is based on the limiting-dilution-
analysis (LDA), recipients received either
540000, 180000, 60000 or 20000 cells per
mouse (n per dilution=5). (G) Frequency of
cobblestone forming areas (CAs) formed by
HSCs from the BM of wild-type mice after
pre-treatment of FBMD1-feeder cells for 10
days with estradiol. (H) Percentage of CFSE-
positive cells in the vascular niche of control
and estradiol treated mice 15 h after injec-
tion of 1 million CFSE-labeled wild-type BM
cells. (I) Relative mRNA-expression of F-
Spondin 1 and CD34 in FBMD1-cells, ten
days after estradiol treatment. (J)
Percentage of LSK-cells in the blood of con-
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Importantly, the frequency of vascular HSCs, reflected by
CRUs, was also increased in ERα knockout mice (Figure 2F).
These data confirm that the increase in estradiol-dependent
changes in bone mass are independent of HSCs both in the
endosteal and vascular compartment. Taken together, both
ERs are either redundant for the phenotype resulting from
estradiol treatment in the vascular HSC niche or the effects
are mediated by another receptor, such as the membrane
bound GPR30.23,24
Estradiol causes stem cell extrinsic alterations 
in the vascular HSC niche
To investigate the estradiol induced microenvironmental
alterations we mimicked the niche by flask bone marrow
Dexter-1 (FBMD1) cells, a murine preadipose stromal feeder
cell line that is very efficient for maintaining HSCs in vitro.13
FBMD1 cells were pre-treated for 14 days with estradiol fol-
lowed by seeding of untreated wild-type BM cells in LDA.
Pre-treatment of FBMD1 with estradiol leads to increased
CA formation (Figure 2G) underscoring the fact that estrogen
action on stromal cells can indirectly enhance HSC numbers.
Next, we performed a homing experiment with CFSE
labeled untreated BM cells transplanted into estradiol treat-
ed recipients. Fifteen hours after homing, the vascular niche
of estradiol treated recipients retained more CFSE positive
cells than control treated recipients (Figure 2H). We con-
clude that estradiol does alter the microenvironmental cells
resulting in increased HSC interactions as a prerequisite to
an increase in HSC numbers. 
Accordingly, we found a stronger retention of LSK cells in
the BM upon estradiol treatment displayed by decreased
LSK numbers in the peripheral blood (Figure 2I). Finally, we
detected upregulation of CD34 and F-Spondin1 mRNA,
both involved in cell adhesion, in estradiol treated FBMD1
cells (Figure 2J) and a tendency for enhanced expression in
primary stromal cells (Online Supplementary Figure S2C and
D). These data suggest that molecules involved in the mobi-
lization and regulation of HSCs mediate estradiol effects in
the vascular BM niche.
Conclusions
We demonstrate that estradiol leads to increased num-
bers of HSCs in the vascular niche but not in the endosteal
niche of BM. This occurs also in the absence of increased
bone mass in ERα knockout mice. Thus the increase in HSC
number induced by estradiol is independent of estradiol
effects on the bone. The increase in HSC numbers is due to
enhanced cell cycle entry leading to HSC exhaustion and
diminished long-term potential determined by serial trans-
plantation. Here, we describe for the first time the differen-
tial effects of estrogens on HSCs in interaction with their
vascular niche.
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